CSF3 and breast carcinoma: For instance, although ciprofloxacin is associated with higher rates of febrile neutropenia than G-CSF in early breast cancer, the incremental cost-effectiveness ratio of G-CSF vs ciprofloxacin was estimated at $1.76 million CAD per quality-adjusted life-year gained, much higher than the commonly used willingness-to-pay value of $50 000 CAD per quality-adjusted life-year.32